GCG and type 2 diabetes mellitus: Therefore, this study investigated UKA outcomes in patients receiving GLP-1 agonists.<h4>Methods</h4>Adult patients with T2DM and/or obesity undergoing UKA between 2009 and 2022 were identified utilizing an administrative claims database.